search
Back to results

Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis

Primary Purpose

Onychomycosis

Status
Completed
Phase
Phase 2
Locations
Sweden
Study Type
Interventional
Intervention
MOB015
Sponsored by
Moberg Pharma AB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Onychomycosis focused on measuring distal subungual onychomycosis

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female
  2. 18 - 70 years
  3. DSO of at least one of the great toe(s) affecting 25 % to 75 % of the target nail (verified by blinded assessor before randomization)
  4. Positive culture for dermatophytes (i.e. Trichophyton species; T. rubrum or T. mentagrophytes)
  5. Signed written informed consent

Exclusion Criteria:

  1. Proximal subungual onychomycosis
  2. DSO of both great toenails where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 2 mm)
  3. "Spike" of onychomycosis extending to eponychium of the target nail
  4. Presence of dermatophytoma (defined as demarcated and localised thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail
  5. Other conditions than DSO known to cause abnormal nail appearance
  6. Topical antifungal treatment of the nails within 1 month before screening
  7. Systemic use of antifungal treatment within 3 months before screening
  8. Signs of severe peripheral circulatory insufficiency
  9. Immunosuppression
  10. Participation in another clinical trial with an investigational drug or device during the previous 4 weeks before screening
  11. Known allergy to any of the tested treatment products
  12. A pregnancy test indicating pregnancy in a woman of childbearing potential at screening (visit 1)
  13. Pre-menopausal (last menstruation ≤ 1 year prior to screening) sexually active women who :

    • are pregnant or nursing
    • are not surgically sterile
    • are of child bearing potential and not practising an acceptable method of birth control, or does not plan to continue practising an acceptable method of birth control throughout the trial (acceptable methods include intrauterine

Sites / Locations

  • 15 Locations

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

MOB015 for 3 months

MOB015 for 9 months

Arm Description

Outcomes

Primary Outcome Measures

Mycological cure of target nail at 12 months, defined as negative fungal culture and negative direct microscopy.

Secondary Outcome Measures

Proportion of patients with negative fungal culture, negative direct microscopy and complete cure.

Full Information

First Posted
November 19, 2010
Last Updated
October 24, 2012
Sponsor
Moberg Pharma AB
search

1. Study Identification

Unique Protocol Identification Number
NCT01246518
Brief Title
Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis
Official Title
An Open, Multi-centre Trial Comparing the Efficacy and Safety of Two Different Treatment Regimens of Topical MOB015 Treatment of Distal Subungual Onychomycosis (DSO)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2011
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
October 2012 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Moberg Pharma AB

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Onychomycosis is a fungal infection that affects fingernails and/or toenails. The purpose of this trial is to investigate if MOB015 is effective and safe for treatment of patients with fungal infection of the toenails.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Onychomycosis
Keywords
distal subungual onychomycosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
250 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
MOB015 for 3 months
Arm Type
Active Comparator
Arm Title
MOB015 for 9 months
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
MOB015
Intervention Description
Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
Primary Outcome Measure Information:
Title
Mycological cure of target nail at 12 months, defined as negative fungal culture and negative direct microscopy.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Proportion of patients with negative fungal culture, negative direct microscopy and complete cure.
Time Frame
1, 3, 6, 9, 12 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female 18 - 70 years DSO of at least one of the great toe(s) affecting 25 % to 75 % of the target nail (verified by blinded assessor before randomization) Positive culture for dermatophytes (i.e. Trichophyton species; T. rubrum or T. mentagrophytes) Signed written informed consent Exclusion Criteria: Proximal subungual onychomycosis DSO of both great toenails where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 2 mm) "Spike" of onychomycosis extending to eponychium of the target nail Presence of dermatophytoma (defined as demarcated and localised thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail Other conditions than DSO known to cause abnormal nail appearance Topical antifungal treatment of the nails within 1 month before screening Systemic use of antifungal treatment within 3 months before screening Signs of severe peripheral circulatory insufficiency Immunosuppression Participation in another clinical trial with an investigational drug or device during the previous 4 weeks before screening Known allergy to any of the tested treatment products A pregnancy test indicating pregnancy in a woman of childbearing potential at screening (visit 1) Pre-menopausal (last menstruation ≤ 1 year prior to screening) sexually active women who : are pregnant or nursing are not surgically sterile are of child bearing potential and not practising an acceptable method of birth control, or does not plan to continue practising an acceptable method of birth control throughout the trial (acceptable methods include intrauterine
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jan Faergemann, MD, PhD
Organizational Affiliation
Dept. of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
15 Locations
City
Sweden
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis

We'll reach out to this number within 24 hrs